Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.

Piu C, Ibba G, Bertoli D, Capra R, Uleri E, Serra C, Imberti L, Dolei A.

J Neurovirol. 2019 Aug 29. doi: 10.1007/s13365-019-00793-4. [Epub ahead of print]

PMID:
31468472
2.

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R.

Neurotherapeutics. 2019 Aug 26. doi: 10.1007/s13311-019-00776-7. [Epub ahead of print]

PMID:
31452081
3.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
4.

Impact of natural menopause on multiple sclerosis: a multicentre study.

Baroncini D, Annovazzi PO, De Rossi N, Mallucci G, Torri Clerici V, Tonietti S, Mantero V, Ferrò MT, Messina MJ, Barcella V, La Mantia L, Ronzoni M, Barrilà C, Clerici R, Susani EL, Fusco ML, Chiveri L, Abate L, Ferraro O, Capra R, Colombo E, Confalonieri P, Zaffaroni M.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1201-1206. doi: 10.1136/jnnp-2019-320587. Epub 2019 Jun 12.

PMID:
31189614
5.

Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Scarpazza C, De Rossi N, Tabiadon G, Turrini MV, Gerevini S, Capra R.

Neurol Sci. 2019 Oct;40(10):2119-2124. doi: 10.1007/s10072-019-03959-4. Epub 2019 Jun 7.

PMID:
31175467
6.

Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.

Scarpazza C, Signori A, Cosottini M, Sormani MP, Gerevini S, Capra R.

Mult Scler. 2019 May 30:1352458519854162. doi: 10.1177/1352458519854162. [Epub ahead of print]

PMID:
31144589
7.

Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.

Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L.

Mult Scler. 2019 Jul;25(8):1196-1201. doi: 10.1177/1352458519832259. Epub 2019 Apr 9.

PMID:
30964396
8.

Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders.

Mariotto S, Ferrari S, Gastaldi M, Franciotta D, Sechi E, Capra R, Mancinelli C, Schanda K, Alberti D, Orlandi R, Bombardi R, Zuliani L, Zoccarato M, Benedetti MD, Tanel R, Calabria F, Rossi F, Pavone A, Grazian L, Sechi G, Batzu L, Murdeu N, Janes F, Fetoni V, Fulitano D, Stenta G, Federle L, Cantalupo G, Reindl M, Monaco S, Gajofatto A.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1293-1296. doi: 10.1136/jnnp-2018-320287. Epub 2019 Apr 5. No abstract available.

PMID:
30952681
9.

Implementing a perioperative efficiency initiative for orthopedic surgery instrumentation at an academic center: A comparative before-and-after study.

Capra R, Bini SA, Bowden DE, Etter K, Callahan M, Smith RT, Vail TP.

Medicine (Baltimore). 2019 Feb;98(7):e14338. doi: 10.1097/MD.0000000000014338.

10.

Intraoperative cell salvage with autologous transfusion in liver transplantation.

Pinto MA, Chedid MF, Sekine L, Schmidt AP, Capra RP, Prediger C, Prediger JE, Grezzana-Filho TJ, Kruel CR.

World J Gastrointest Surg. 2019 Jan 27;11(1):11-18. doi: 10.4240/wjgs.v11.i1.11. Review.

11.

Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):261-267. doi: 10.1136/jnnp-2018-319208. Epub 2018 Nov 2.

PMID:
30389778
12.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

13.

Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder.

Bo M, Niegowska M, Arru G, Sechi E, Mariotto S, Mancinelli C, Farinazzo A, Alberti D, Gajofatto A, Ferrari S, Capra R, Monaco S, Sechi G, Sechi LA.

J Neuroimmunol. 2018 May 15;318:97-102. doi: 10.1016/j.jneuroim.2018.02.013. Epub 2018 Feb 28.

PMID:
29519720
14.

Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.

Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, Rossi S, Pitteri M, Benedetti MD, Gajofatto A, Pizzini FB, Montemezzi S, Rasia S, Capra R, Bertoldo A, Facchiano F, Monaco S, Reynolds R, Calabrese M.

Ann Neurol. 2018 Apr;83(4):739-755. doi: 10.1002/ana.25197.

16.

Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?

Mancinelli CR, Scarpazza C, Santuccio G, De Rossi N, Capra R.

Neurol Sci. 2018 May;39(5):965-966. doi: 10.1007/s10072-017-3228-7. Epub 2018 Jan 4. No abstract available.

PMID:
29302813
17.

Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status.

S M, A F, S M, A G, G Z, K S, R C, C M, A B, R B, M R, S F.

Mult Scler J Exp Transl Clin. 2017 Nov 22;3(4):2055217317743098. doi: 10.1177/2055217317743098. eCollection 2017 Oct-Dec.

18.

Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder.

Arru G, Sechi E, Mariotto S, Farinazzo A, Mancinelli C, Alberti D, Ferrari S, Gajofatto A, Capra R, Monaco S, Deiana GA, Caggiu E, Mameli G, Sechi LA, Sechi GP.

Mult Scler J Exp Transl Clin. 2017 Nov 22;3(4):2055217317742425. doi: 10.1177/2055217317742425. eCollection 2017 Oct-Dec.

19.

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group.

J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23.

20.

Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.

Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, De Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi G, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A.

J Neurol. 2017 Dec;264(12):2420-2430. doi: 10.1007/s00415-017-8635-4. Epub 2017 Oct 23.

21.

To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.

Scarpazza C, Prosperini L, De Rossi N, Moiola L, Sormani MP, Gerevini S, Capra R; Italian PML group.

Ann Neurol. 2017 Nov;82(5):697-705. doi: 10.1002/ana.25070. Epub 2017 Oct 31.

PMID:
29023856
22.

Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy.

Groppo E, Baglio F, Cattaneo D, Tavazzi E, Bergsland N, Di Tella S, Parelli R, Carpinella I, Grosso C, Capra R, Rovaris M.

Front Neurol. 2017 Sep 19;8:491. doi: 10.3389/fneur.2017.00491. eCollection 2017.

23.

Altered bodily self-consciousness in multiple sclerosis.

Nava E, Mattioli F, Gamberini C, Stampatori C, Bellomi F, Turati C, Capra R, Bolognini N.

J Neuropsychol. 2018 Sep;12(3):463-470. doi: 10.1111/jnp.12134. Epub 2017 Sep 10.

PMID:
28891265
24.

Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Sep 15;380:19. doi: 10.1016/j.jns.2017.06.037. Epub 2017 Jul 4. No abstract available.

PMID:
28870565
25.

Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Rossi F, Prosperini L, De Rossi N, Capra R, Rivanera D, Li X, Cinque P, Passeri L, Pozzilli C, Viscidi R.

Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.

PMID:
28836899
26.

MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.

De Meo E, Moiola L, Ghezzi A, Veggiotti P, Capra R, Amato MP, Pagani E, Fiorino A, Pippolo L, Pera MC, Comi G, Falini A, Filippi M, Rocca MA.

Neurology. 2017 Sep 19;89(12):1265-1273. doi: 10.1212/WNL.0000000000004388. Epub 2017 Aug 18.

27.

Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R.

J Neurovirol. 2017 Oct;23(5):742-749. doi: 10.1007/s13365-017-0561-9. Epub 2017 Aug 8.

PMID:
28791614
28.

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Jul 15;378:233-237. doi: 10.1016/j.jns.2017.05.018. Epub 2017 May 12. Erratum in: J Neurol Sci. 2017 Sep 15;380:19.

PMID:
28566170
29.

Association between cardiovascular disease risk scores and subclinical atherosclerosis prevalence in non-elderly adult patients from Argentina.

Albertini RA, Ferrer DG, Romagnoli PA, Tinti ME, Amigone JL, Capra R, Chiabrando GA.

Int J Cardiovasc Imaging. 2017 Oct;33(10):1521-1529. doi: 10.1007/s10554-017-1152-9. Epub 2017 May 10.

PMID:
28493105
30.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group.

Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22.

31.

Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.

Capra R, Cordioli C, Rasia S, Gallo F, Signori A, Sormani MP.

Mult Scler. 2017 Nov;23(13):1757-1761. doi: 10.1177/1352458516687402. Epub 2017 Jan 12.

PMID:
28080255
32.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

33.

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.

Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, Capra R; Italian PML study group.

PLoS One. 2016 Dec 20;11(12):e0168376. doi: 10.1371/journal.pone.0168376. eCollection 2016.

34.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22.

PMID:
27878443
35.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

36.

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.

Diotti RA, Capra R, Moiola L, Caputo V, De Rossi N, Sangalli F, Martinelli V, Burioni R, Clementi M, Mancini N.

Viruses. 2016 May 7;8(5). pii: E128. doi: 10.3390/v8050128.

37.

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Mattioli F, Bellomi F, Stampatori C, Provinciali L, Compagnucci L, Uccelli A, Pardini M, Santuccio G, Fregonese G, Pattini M, Allegri B, Clerici R, Lattuada A, Montomoli C, Corso B, Gallo P, Riccardi A, Ghezzi A, Roscio M, Tola MR, Calanca C, Baldini D, Trafficante D, Capra R.

Front Behav Neurosci. 2016 Feb 23;10:28. doi: 10.3389/fnbeh.2016.00028. eCollection 2016.

38.

Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy.

Loraschi A, Bellantonio P, Bortolon F, Capra R, Cavalla P, Costantino G, Lugaresi A, Martinelli V, Marrosu MG, Patti F, Rottoli M, Salvetti M, Sola P, Solaro C, Klersy C, Marino F, Zaffaroni M, Cosentino M.

Neurol Sci. 2016 Apr;37(4):613-22. doi: 10.1007/s10072-016-2519-8. Epub 2016 Feb 19.

PMID:
26895323
39.

Bilateral visual loss recovering after tadalafil withdrawal.

Cordioli C, Capra R.

Neurol Sci. 2016 May;37(5):809-10. doi: 10.1007/s10072-015-2447-z. Epub 2015 Dec 23. No abstract available.

PMID:
26700798
40.

Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis.

Rocca MA, Morelli ME, Amato MP, Moiola L, Ghezzi A, Veggiotti P, Capra R, Pagani E, Portaccio E, Fiorino A, Pippolo L, Pera MC, Comi G, Falini A, Filippi M.

Mult Scler. 2016 Apr;22(5):628-40. doi: 10.1177/1352458515598569. Epub 2015 Aug 18.

PMID:
26286701
41.

Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.

Bertoli D, Serana F, Sottini A, Cordioli C, Maimone D, Amato MP, Centonze D, Florio C, Puma E, Capra R, Imberti L.

PLoS One. 2015 Aug 18;10(8):e0135441. doi: 10.1371/journal.pone.0135441. eCollection 2015.

42.

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.

Mattioli F, Stampatori C, Bellomi F, Scarpazza C, Capra R.

PLoS One. 2015 Jul 6;10(7):e0131803. doi: 10.1371/journal.pone.0131803. eCollection 2015.

43.

Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.

Mattioli F, Bellomi F, Stampatori C, Capra R, Miniussi C.

Mult Scler. 2016 Feb;22(2):222-30. doi: 10.1177/1352458515587597. Epub 2015 May 26.

PMID:
26014600
44.

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A.

Mult Scler. 2015 Nov;21(13):1713-22. doi: 10.1177/1352458515570768. Epub 2015 Feb 19.

PMID:
25698174
45.

A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study.

Mattioli F, Stampatori C, Bellomi F, Danni M, Compagnucci L, Uccelli A, Pardini M, Santuccio G, Fregonese G, Pattini M, Allegri B, Clerici R, Lattuada A, Montomoli C, Corso B, Capra R.

Front Neurol. 2015 Jan 13;5:278. doi: 10.3389/fneur.2014.00278. eCollection 2014.

46.

Transient neonatal hyperthyrotropinemia is a risk factor for developing persistent hyperthyrotropinemia in childhood with repercussion on developmental status.

Cuestas E, Gaido MI, Capra RH.

Eur J Endocrinol. 2015 Apr;172(4):483-90. doi: 10.1530/EJE-13-0907. Epub 2015 Jan 20.

PMID:
25603800
47.

Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.

Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.

J Neuroimmunol. 2014 Dec 15;277(1-2):6-12. doi: 10.1016/j.jneuroim.2014.10.011. Epub 2014 Nov 3. Review.

PMID:
25468273
48.

Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions.

Rocca MA, De Meo E, Amato MP, Copetti M, Moiola L, Ghezzi A, Veggiotti P, Capra R, Fiorino A, Pippolo L, Pera MC, Falini A, Comi G, Filippi M.

Mult Scler. 2015 Jun;21(7):956-9. doi: 10.1177/1352458514557303. Epub 2014 Nov 12.

PMID:
25392332
49.

Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.

Chiarini M, Sottini A, Bertoli D, Serana F, Caimi L, Rasia S, Capra R, Imberti L.

Mult Scler. 2015 May;21(6):726-34. doi: 10.1177/1352458514551456. Epub 2014 Nov 12.

PMID:
25392322
50.

Multiple sclerosis progression is not associated with birth timing in Italy.

Lucenti A, Galimberti S, Barizzone N, Naldi P; PROGEMUS Group; PROGRESSO Group, Comi G, Martinelli Boneschi F, D'Alfonso S, Leone MA.

J Neurol Sci. 2014 Nov 15;346(1-2):194-6. doi: 10.1016/j.jns.2014.08.021. Epub 2014 Aug 23.

PMID:
25194635

Supplemental Content

Loading ...
Support Center